Join
Live feed
·
PRReleasevia Quantisnow
Krystal Biotech Inc. logo

Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis

ByQuantisnow·Wall Street's wire, on your screen.
KRYS· Krystal Biotech Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KRYS (Krystal Biotech Inc.) and more on Quantisnow.